Literature DB >> 32671456

Patient selection for salvage surgery after definitive chemoradiotherapy in esophageal squamous cell carcinoma.

Hiroki Harada1, Keishi Yamashita1,2, Chikatoshi Katada3, Hiromichi Ishiyama4, Takafumi Soeno1, Marie Washio1, Mikiko Sakuraya1, Hideki Ushiku1, Masahiro Niihara1, Kei Hosoda1, Naoki Hiki5.   

Abstract

PURPOSE: With the widespread use of definitive chemoradiotherapy (dCRT) for esophageal squamous cell carcinoma (ESCC), salvage surgery for recurrence/residual patients became prevalent. However, survival impact of salvage surgery remains obscure at present.
METHODS: The updated clinical outcomes of salvage surgery were investigated to know its survival impact. Of the 155 ESCC patients who underwent dCRT between 2009 and 2016, we included 85 patients with recurrence or residual disease. The median follow-up was 65 months.
RESULTS: Of the 85 patients with progression disease, there were 42 and 43 patients of recurrence and residual disease, respectively. Salvage surgery was performed in 27 patients after dCRT, including 15 patients who underwent salvage esophagectomy. The 5-year overall survival (OS) of salvage surgery and otherwise patients was 66.1% and 14.5%, and the patients with salvage surgery had a significantly better prognosis (p < 0.0001). In the 15 patients who underwent salvage esophagectomy, residual disease, lymph node metastasis-positive (ycN+) after dCRT, and pathological lymph node metastasis-positive (ypN+) were significantly associated with poor prognosis (p = 0.0492, p = 0.0006, p = 0.0276), and the 5-year OS rates for the ycN/ypN combinations were 90%, 33.3%, and 0% in ycN-/ypN-, ycN+/ypN-, and ycN+/ypN+ patients, respectively (p = 0.0026). In a multivariate analysis, ycN+ was an independent poor prognostic factor (HR 13.6, 95% CI 1.65-286.8, p = 0.0154).
CONCLUSIONS: Survival impact of salvage surgery after dCRT is robust, and lymph node metastasis after dCRT may help determine the indication for salvage esophagectomy.

Entities:  

Keywords:  Definitive chemoradiotherapy; Esophageal cancer; Esophageal squamous cell carcinoma; Prognosis; Salvage surgery

Mesh:

Year:  2020        PMID: 32671456     DOI: 10.1007/s00423-020-01935-7

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  3 in total

1.  Optimized lymph node dissection range during progression of lower thoracic esophageal squamous cell carcinoma in the latest therapeutic surgical strategy: A retrospective analysis.

Authors:  Hiroki Harada; Kei Hosoda; Hiromitsu Moriya; Hiroaki Mieno; Akira Ema; Marie Washio; Yoshimasa Kosaka; Masahiko Watanabe; Keishi Yamashita
Journal:  Oncol Lett       Date:  2018-06-27       Impact factor: 2.967

2.  Clinical significance of chemoradiotherapy and surgical resection for cT4 esophageal cancer.

Authors:  Masaru Morita; Yasushi Toh; Hiroshi Saeki; Masahiko Sugiyama; Kippei Ohgaki; Shin-Ichiro Maehara; Kazuhito Minami; Yasuharu Ikeda; Yoshihisa Sakaguchi; Takeshi Okamura; Satoru Uehara; Yoshihiko Maehara
Journal:  Anticancer Res       Date:  2012-08       Impact factor: 2.480

3.  Association of Preoperative Nutritional Status with Prognosis in Patients with Esophageal Cancer Undergoing Salvage Esophagectomy.

Authors:  Makoto Sakai; Makoto Sohda; Tatsuya Miyazaki; Tomonori Yoshida; Yuji Kumakura; Hiroaki Honjo; Keigo Hara; Daigo Ozawa; Shigemasa Suzuki; Naritaka Tanaka; Takehiko Yokobori; Hiroyuki Kuwano
Journal:  Anticancer Res       Date:  2018-02       Impact factor: 2.480

  3 in total
  2 in total

1.  A re-irradiation dose of 55-60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy.

Authors:  Xun Wu; Xingsheng Hu; Junru Chen; Lang He
Journal:  Radiat Oncol       Date:  2021-06-08       Impact factor: 3.481

Review 2.  Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma.

Authors:  Koichi Yagi; Tetsuro Toriumi; Susumu Aikou; Hiroharu Yamashita; Yasuyuki Seto
Journal:  Ann Gastroenterol Surg       Date:  2021-03-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.